MD Anderson and C-Biomex sign collaborative research agreement to co-develop CBT-001 radioligand therapy
MD Anderso and C-Biomex today announced a strategic collaboration to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.
Source: newswise.com